Fairmount Funds Management LLC

WEST CONSHOHOCKEN, PA · CIK 1802528 · 13F filing filed 2026-08-14

SEC-registered investment adviser since 2019 · limited liability company

Assets managed$5.8bn
Staff30 · 12 in investment roles
Main clients (by assets)Private funds 100%
Private funds6 (1 hedge) · $5.9bn gross assets
Websitefairmountfunds.com
Form ADV · 2026-08-07SEC adviser record

Legal entityFAIRMOUNT FUNDS MANAGEMENT LLC (US)

$1.5bn reported value +9.3% vs Q1 2026

12positions

97.6%in top 10

1 new 1 added 0 reduced 1 sold out vs Q1 2026

Holdings, Q2 2026

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#	Security	Ticker	Shares	Value	% of portfolio	Change	Shares change
1	ORUKA THERAPEUTICS INC COM ORKA	ORKA	3,705,262	$352.6m23.31%	23.31%	Unchanged
2	DIANTHUS THERAPEUTICS INC COM DNTH	DNTH	2,537,191	$247.3m16.35%	16.35%	Unchanged
3	DAMORA THERAPEUTICS INC COM NEW COM NEW		8,713,000	$226.6m14.98%	14.98%	Unchanged
4	COGENT BIOSCIENCES INC COM COGT	COGT	5,503,418	$213.0m14.08%	14.08%	Unchanged
5	JADE BIOSCIENCES INC COM NEW JBIO	JBIO	4,553,494	$101.2m6.69%	6.69%	Unchanged
6	ENLIVEN THERAPEUTICS INC COM ELVN	ELVN	1,855,644	$94.2m6.22%	6.22%	Unchanged
7	VIRIDIAN THERAPEUTICS INC COM VRDN	VRDN	5,090,928	$93.5m6.18%	6.18%	Added +1.2m	+1,176,470 30.1%
8	ZENAS BIOPHARMA INC COM ZBIO	ZBIO	2,359,025	$59.9m3.96%	3.96%	Unchanged
9	CRESCENT BIOPHARMA INC. COM CBIO	CBIO	2,747,866	$49.5m3.27%	3.27%	Unchanged
10	APOGEE THERAPEUTICS INC COM COM		298,647	$39.6m2.62%	2.62%	Unchanged
11	FAETH THERAPEUTICS INC COM NEW FTH	FTH	722,020	$18.1m1.19%	1.19%	New
12	INHIBIKASE THERAPEUTICS INC COM NEW IKT	IKT	8,625,000	$17.5m1.16%	1.16%	Unchanged

Sold out since Q1 2026

Security	Ticker	Shares held before	Value then
SPYRE THERAPEUTICS INC SYRE	SYRE	4,018,101	$202.7m4.0m shares

Stakes above 5%

Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.

Company	Ticker	Stake	Change	Schedule	Last filed
ALAUNOS THERAPEUTICS INC TCRT · 13D · filed 2026-10-15	TCRT	20.0%≈ $1.3m	new	13D	2026-10-15
JADE BIOSCIENCES INC JBIO · 13D · filed 2026-06-09	JBIO	20.0%≈ $310.7m	no change	13D	2026-06-09
DAMORA THERAPEUTICS INC 13D · filed 2026-02-11		20.0%≈ $226.6m	no change	13D	2026-02-11
ORUKA THERAPEUTICS INC ORKA · 13D · filed 2026-07-01	ORKA	19.5%≈ $1.4bn	-0.5 pts	13D	2026-07-01
CRESCENT BIOPHARMA INC. CBIO · 13D · filed 2026-07-20	CBIO	16.5%≈ $118.8m	-2.0 pts	13D	2026-07-20
VIRIDIAN THERAPEUTICS INC VRDN · 13D · filed 2026-05-13	VRDN	14.0%≈ $316.0m	-1.1 pts	13D	2026-05-13
SPYRE THERAPEUTICS INC SYRE · 13D · filed 2026-10-09	SYRE	10.0%≈ $860.2m	no change	13D	2026-10-09
INHIBIKASE THERAPEUTICS INC IKT · 13G · filed 2026-02-17	IKT	9.9%≈ $25.3m	no change	13G	2026-02-17
COGENT BIOSCIENCES INC COGT · 13D · filed 2026-03-31	COGT	8.6%≈ $594.3m	-1.3 pts	13D	2026-03-31

Trades reported as a company insider since 1 Apr 2026

Owning 10% or more of a company, or having someone on its board, makes this manager an insider there: it reports its trades in that company's shares on Form 4 within two business days. Open-market and private purchases and sales only.

Date	Company	Ticker	Trade	Shares	Value	Their holding
2026-07-16	CRESCENT BIOPHARMA INC. Director · By Fairmount Healthcare Fund II L.P.	CBIO	Bought	853,450	$12.4m853.5k shares	+31%
2026-07-01	ORUKA THERAPEUTICS INC Director · By Fairmount Healthcare Fund II L.P.	ORKA	Sold	3,553,410	$300.0m3.6m shares	-76%
2026-06-23	SPYRE THERAPEUTICS INC Director · By Fairmount Healthcare Fund II L.P.	SYRE	Sold	4,684,781	$399.7m4.7m shares	-100%
2026-05-11	VIRIDIAN THERAPEUTICS INC Director · By Fairmount Healthcare Fund II L.P.	VRDN	Bought	1,176,470	$20.0m1.2m shares	+30%